前蛋白转化酶枯草溶菌素/kexin 6型(PCSK6)可能是膜性肾病及非甾体抗炎药使用中的抗原靶点
研究对250例PLA2R阴性膜性肾病行激光显微切割联合质谱分析,发现5例有PCSK6高光谱计数,验证队列另检出8例;13例中10例有重度非甾体抗炎药使用史,IgG与PCSK6共定位,提示PCSK6可能是长期使用非甾体抗炎药患者膜性肾病的可能新抗原靶点。
要点
- 在PLA2R阴性膜性肾病中,质谱发现5例PCSK6高光谱计数,验证队列另检出8例。
- 13例PCSK6相关病例中10例有重度非甾体抗炎药使用史,1例病史不可得。
- 肾活检时平均血清肌酐0.93±0.47 mg/dL,平均蛋白尿6.5±3.3 g/天。
核心结论
- PCSK6可能是长期使用非甾体抗炎药患者膜性肾病的可能新抗原靶点。
研究设计与样本
- 对250例PLA2R阴性膜性肾病行肾小球激光显微切割联合质谱分析以发现新抗原靶点,并设验证队列。
- 验证队列采用蛋白G免疫沉淀、质谱和免疫荧光检测PCSK6。
主要发现
- 发现队列250例中5例PCSK6总光谱计数高,验证队列另检出8例PCSK6,所有病例已知抗原阴性。
- 13例PCSK6相关病例中10例有重度非甾体抗炎药使用史,1例病史不可得。
- 肾活检时平均血清肌酐0.93±0.47 mg/dL,平均蛋白尿6.5±3.3 g/天。
- 免疫组化/免疫荧光示PCSK6沿肾小球基底膜颗粒状沉积,共聚焦显微镜示IgG与PCSK6共定位。
- 3例IgG亚类分析示IgG1和IgG4共优势;洗脱液Western blot示PCSK6相关膜性肾病IgG结合PCSK6,而PLA2R阳性膜性肾病不结合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drugs are an important secondary cause of membranous nephropathy (MN) with the most common drugs associated with MN being nonsteroidal anti-inflammatory drugs (NSAIDs). Since the target antigen in NSAID-associated MN is not known, we performed laser microdissection of glomeruli followed by mass spectrometry (MS/MS) in 250 cases of PLA2R-negative MN to identify novel antigenic targets. This was followed by immunohistochemistry to localize the target antigen along the glomerular basement membrane and western blot analyses of eluates of frozen biopsy tissue to detect binding of IgG to the novel antigenic target. MS/MS studies revealed high total spectral counts of a novel protein Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK 6) in five of the 250 cases in the discovery cohort. A validation cohort using protein G immunoprecipitation, MS/MS, and immunofluorescence detected PCSK6 in eight additional cases. All cases were negative for known antigens. Ten of 13 cases had a history of heavy NSAID use with no history available in one case. The mean serum creatinine and proteinuria at kidney biopsy were 0.93 ± 0.47 mg/dL and 6.5 ± 3.3 gms/day, respectively. Immunohistochemistry/immunofluorescence showed granular staining for PCSK6 along the glomerular basement membrane, and confocal microscopy showed co-localization of IgG and PCSK6. IgG subclass analysis in three cases revealed codominance of IgG1 and IgG4. Western blot analysis using eluates from frozen tissue showed IgG binding to PCSK6 in PCSK6-associated but not in PLA2R-positive MN. Thus, PCSK6 may be a likely novel antigenic target in MN in patients with prolonged NSAID use.
引用
- Sethi S, Casal Moura M, Madden B, et al. Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. Kidney Int. 2023. PMID: 37119877. doi:10.1016/j.kint.2023.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。